Take the above results together, we implied that bortezomib could inhibit the proteasome degradation of p21 and p27 by targeting proteasome subunit PSMD2, PSMB1 and PSMB5, to induce cell cycle arrest and inhibit the proliferation of NSCLC cells. Here, PSMD2 is linked to non-small cell lung carcinoma.